Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — SeQuent Scientific — Q3 FY21 Earnings Presentation
21 slides from Viyash Scientific's earnings presentation, Feb 3, 2021
Slide 1: Proven Ability In Life Sciences
Proven Ability In Life Sciences February 3, 2021 BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex, Dalal Street, Fort, Bandra (East), Mumbai – 400 001. Mumbai – 400 051. Scrip cod
Slide 2: Execution focus ensures Revenue and Margin momentum
SeQuent Announces Q3 and 9M FY21 results: Execution focus ensures Revenue and Margin momentum Q3 FY21 - Revenues at Rs. 3,582 Million up by 13.2%, EBITDA at Rs. 651 Million up 34.5% Mumbai, February 3, 2021 SeQuent Scientific Limited (SeQuent), which has businesses across Animal Health (Alivira) & A
Slide 3: Earnings Call with Investors
Earnings Call with Investors The Company will conduct an Earnings call at 8:45 AM IST on February 4, 2021 where the Management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahe
Slide 4: Earnings Presentation Q3 & 9MFY21
Earnings Presentation Q3 & 9MFY21 February 3, 2021
Slide 5: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "pl
Slide 6: Management Commentary
Management Commentary “We are pleased to report another strong quarter of performance across all key parameters; while revenues have grown 15.5%, the EBITDA has grown by 42% with a 325 bps margin improvement in the first nine months. With a growth of 66% in net profits, the business generated ₹ 1.6
Slide 7: Q3 and 9M FY21 Performance Review
Q3 and 9M FY21 Performance Review
Slide 8: Steady Performance
Steady Performance Q3 FY21 YoY 9M FY21 YoY Q3 FY21 3,582 9M FY21 10,148 Revenues 13.2% 15.5% Q3 FY20 3,164 9M FY20 8,787 Q3 FY21 651 9M FY21 1,770 EBITDA 34.5% 41.9% Q3 FY20 484 9M FY20 1,247 Q3 FY21 372 9M FY21* 878 PAT 83.3% 65.6% Q3 FY20 203 9M FY20 531 Q3 FY21 667 9M FY21 1,684 Cash from Operati
Slide 9: Execution focus ensures momentum
Execution focus ensures momentum All values in ₹ Mn YoY% YoY% Revenue Distribution Q3 FY21 Q3 FY20 YoY% 9M FY21 9M FY20 YoY% (Constant Currency) (Constant Currency) Formulations 2,285 2,113 8.2% 12.7% 6,549 5,855 11.9% 15.0% Europe 1,025 974 5.3% (5.6%) 3,050 2,700 13.0% 2.7% LATAM 424 287 47.9% 87.
Slide 10: Alivira wins again at the IHS Animal Pharm 2020 Awards
Alivira wins again at the IHS Animal Pharm 2020 Awards Alivira is awarded the best Company in Animal health from India/Middle East/Africa Region This is the second year in succession when IHS Markit Animal Health has chosen Alivira for this honour and takes into account our continuing strong out-per
Slide 11: Q3 & 9M FY21 Business Review
Sequent | & Proven Ability In Life Sciences Q3 & 9M FY21 Business Review J
Slide 12: Formulations building on the globally diversified presence
Formulations building on the globally diversified presence… Highlights FDFs 1000+ Europe subdued due to the operational challenges of the second wave of Covid • Spain & Germany impacted while Benelux & Sweden reported strong growth • European growth to accelerate as we gain traction in our recent la
Slide 13: APIs deepening relationship with global AH players
... APIs deepening relationship with global AH players… Commercial 27 Highlights Highlights APIs Highest quarterly sales of ₹1,297Mn with growth of 20.0% 1/3rd sales from global Top-10 AH players in 9M Manufacturing 3 11 CEP & 21 US filings/approvals in total (1 CEP approval and 1 USVMF filing in Q3
Slide 14: Focused R&D Initiatives to drive future growth
… Focused R&D Initiatives to drive future growth Formulations Highlights Highlights Filings in Products Under Injectables 35+ R&D Centres 4 38% US in next 3 10 Development years API Molecules in US Filings CEP Approvals 14+ R&D Centre 1 21 11 pipeline 11 11
Slide 15: Financials
Sequent & Proven Ability In Life Sciences @ ail st teug 5} tn WG
Slide 16: Consolidated Financials: Q3 and 9M FY21
Consolidated Financials: Q3 and 9M FY21 All values in ₹Mn Q3 FY21 Q2 FY21 Q3 FY20 9M FY21 9M FY20 FY20 PARTICULARS Unaudited Unaudited Unaudited Unaudited Unaudited Audited Revenue from Operations 3,582 3,463 3,164 10,148 8,787 11,792 Material Consumption (1,784) (1,807) (1,618) (5,186) (4,556) (6,0
Slide 17: Key Balance Sheet Items
Key Balance Sheet Items All values in ₹Mn Particulars Dec-20 Sep-20 Mar-20 Balance Sheet Highlights Shareholders Funds 7,953 7,483 7,428 Cash flow generation of ₹1.5Bn+ from operations drives net debt reduction of ₹975Mn in 9M Minority Interest 511 478 447 Prepayment of all INR denominated term loan
Slide 18: Strengthening financial performance over the years
Strengthening financial performance over the years EBITDA Margin Net debt to EBITDA ROCE* 17.4% 21.4% 2.81 14.9% 14.7% 12.8% 1.90 11.7% 10.3% 1.30 7.8% 0.55 FY18 FY19 FY20 9MFY21* FY18 FY19 FY20 9MFY21* FY18 FY19 FY20 9MFY21* Judicious capital utilization and operating leverage leads to 2.5x growth
Slide 19: Delivering on guidance
Delivering on guidance FY21 New members in Board and Advisory Consolidation of New Promoter Subsidiaries FY21 Outlook 9MFY21 status ▪ High-teen ▪ 15.5% revenue revenue growth Consolidation of growth Strong Analytical lab Financials ▪ 200+ bps margin Partnering ▪ 325 bps margin expansion industry lea
Slide 20: Thank You
Thank You 1 7
Slide 21: For details, feel free to contact
For details, feel free to contact: Tushar Mistry Abhishek Singhal Diwakar Pingle Chief Financial Officer Investor Relations Consultant Christensen Investor Relations +91 22 4111 4717 abhishek.s@sequent.in +91 22 4215 0210 tushar.m@sequent.in dpingle@christensenir.com Registered Office: 301/A, ‘Dosti